-
Article
Open AccessNivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study
-
Article
Open AccessUltra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
Mutations of ABL1 are the dominant mechanism of relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). We performed highly accurate Duplex Sequencing of exons 4–10 of ABL1 on bone ma...
-
Article
Open AccessImpact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
FLT3-ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3-ITD diversity can further influence clinical outcomes. Addition of FLT3 inhibitors to stand...
-
Article
Open AccessPhase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated i...
-
Article
Open AccessDesign and rationale for the life after stop** tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduc...
-
Article
Open AccessEffect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms (MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an...
-
Article
Erratum: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Nature Reviews Drug Discovery 10, 127–140 (2011) The information presented in Table 2 on the compound SB1518 was incorrect; the correct information is provided below, and has been corrected online.
-
Article
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'